Bio-Techne shareholders voted overwhelmingly Wednesday to approve the company's $11.3 billion acquisition by German pharmaceutical giant Merck KGaA, clearing the final major hurdle for what will become the largest deal in the life sciences tools sector in a decade. The special shareholder meeting came three months after Merck announced its $73-per-share all-cash offer for the Minnesota-based company, valuing Bio-Techne at nearly double its pre-announcement trading price.

The merger approval marks a significant milestone in Merck's strategy to expand its portfolio of research reagents and diagnostic tools. Bio-Techne, which has spent 50 years building a catalog of high-quality antibodies, proteins, and assays used by scientists worldwide, will give Merck immediate access to thousands of research customers and a distribution network spanning six continents.

The Deal That Reshaped the Sector

Merck's bid for Bio-Techne represents the boldest consolidation move in life sciences since Thermo Fisher Scientific acquired PPD for $17.4 billion in 2021. The $11.3 billion price tag reflects both Bio-Techne's market position and Merck's willingness to pay a premium to secure a company that generates consistent cash flow and serves an irreplaceable role in drug discovery pipelines.

Bio-Techne's product catalog includes some of the most widely used research tools in molecular biology. Its R&D Systems brand is considered the gold standard for cell culture reagents, while its Novus Biologicals division supplies antibodies to nearly every major pharmaceutical company and academic research institution. These are not commodities that can be easily replaced—they're specialized products that scientists trust for reproducibility and consistency.

Why Merck Paid a 95 Percent Premium

When Merck announced the deal on June 25, Bio-Techne's stock was trading around $37 per share. The $73-per-share offer represented a 95 percent premium, one of the richest premiums paid for a life sciences company in recent memory. That price suggests Merck sees something beyond Bio-Techne's current revenue stream—it sees a strategic asset that complements its existing pharmaceutical business.

Merck already operates a life sciences division that sells chemicals and lab equipment to researchers, but Bio-Techne's reagent portfolio fills critical gaps. The acquisition gives Merck a complete toolkit for gene editing, protein analysis, and cellular assays, positioning the combined company as a one-stop shop for scientists running experiments in oncology, immunology, and neuroscience.

The premium also reflects the competitive landscape. Bio-Techne was not actively seeking a buyer, which meant Merck had to make an offer compelling enough to convince management and shareholders to sell rather than continue building the company independently. At $73 per share, the deal became impossible to refuse.

The Regulatory Path Ahead

Wednesday's shareholder vote was the easy part. The deal still requires regulatory approval from antitrust authorities in the United States and Europe, a process that could take months. The Hart-Scott-Rodino waiting period under U.S. antitrust law expired on September 18, removing one obstacle, but the Federal Trade Commission could still request additional information or challenge the merger if it believes the combination would harm competition.

European regulators will likely scrutinize whether the merger gives Merck too much control over the reagents market, particularly in regions where Bio-Techne and Merck's existing life sciences division compete directly. If regulators demand divestitures, Merck may have to sell certain product lines to win approval, which could reduce the strategic value of the acquisition.

Bio-Techne and Merck are targeting a close date in late 2026 or early 2027, assuming no major regulatory challenges emerge. That timeline suggests both companies believe the deal will clear antitrust review without significant concessions, but the regulatory process remains the biggest remaining risk.

What This Means for Researchers

For the thousands of scientists who use Bio-Techne's products daily, the merger raises immediate questions about pricing and availability. Consolidation in the life sciences tools sector has historically led to price increases, as larger companies leverage their market position to extract higher margins. Bio-Techne's antibodies and reagents are already premium-priced compared to generic alternatives, and some researchers worry Merck will push prices even higher.

On the other hand, Merck's global scale could improve Bio-Techne's distribution network, making products more accessible in regions where Bio-Techne previously lacked a strong presence. Merck's manufacturing capabilities could also reduce supply chain bottlenecks that have plagued the industry since 2024, when shortages of key reagents delayed experiments and clinical trials worldwide.

The Bigger Picture

The Bio-Techne acquisition is part of a broader wave of consolidation in the life sciences sector, as large pharmaceutical companies seek to control more of the research supply chain. By owning the tools scientists use to discover new drugs, companies like Merck gain insight into emerging research areas before they become mainstream, allowing them to make acquisitions or investments ahead of competitors.

Bio-Techne will cease to exist as a publicly traded company once the deal closes, ending a 50-year run as an independent operator. The company's employees, intellectual property, and customer relationships will be absorbed into Merck's life sciences division, which already employs more than 10,000 people globally. For Bio-Techne shareholders who voted yes on Wednesday, the $73-per-share payout represents a windfall. For the researchers who rely on Bio-Techne's products, the real test comes after the merger closes and they see whether the quality and service they've come to expect remain intact under new ownership.